With Pfizer dr NP said in the last 4 years , they observing what diseases they going with Maraviroc , since this is also CCR5 inhibitor , this is why cydy started with GvHD , after positive results were noticed with Maraviroc , they talking now post stroke which in pre-clinical studies they also using Maraviroc ..,
I actually think it is very smart of them , they don’t just spend money without idea , they going where Maraviroc is already showing positive results , and this is very many diseases ..,

And in the future Maraviroc is not big competitor to Leronlimab , imo because of severe side effects .,

And at some point today Dr NP did say that our mono if positive results will affect Gilead .
I am sure Gilead is looking carefully !!’